Page 3 - Cancer Drugs

AstraZeneca India surrenders marketing approval of prostate cancer drug

AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing. It has now surrendered the marketing authorisation of the indication of Olaparib (Lynparza) 100mg and 150mg, the filing added. "...since the date of receipt of marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India," the company said, adding, "the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons." The drug is indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate ..

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.

Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the cells that break down bone

Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio

Jobevne works by blocking a protein called VEGF, which helps tumours grow new blood vessels

Pfizer's breast cancer drug Vepdegestrant posts mixed results in key trial

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its goals for a subset who have a specific genetic mutation

Apollo Hospitals partners with Ion Beam Applications for proton therapy

Apollo Hospitals on Tuesday said it has tied up with Ion Beam Applications to introduce proton beam therapy solutions for cancer treatment. The healthcare major has tied up with Ion Beam Applications to introduce the Proteus One system in India. "The addition of Proteus One to our Apollo Proton Cancer Centres further solidifies our position as a global leader in Proton Therapy. This next-generation technology will allow us to achieve superior clinical outcomes and significantly improve the quality of life for cancer patients in India and beyond," Apollo Hospitals Enterprise Founder-Chairman Prathap C Reddy said in a statement. As per the study published in The Lancet Regional Health, worldwide in terms of absolute incidence number, following China and the US, India ranks third, contributing 7.5 per cent of all new cancer incidences and is expected to grow to 1.5 million this year. Ion Beam Applications CEO Olivier Legrain said: "These contracts expand upon the close relationship we

Global breast cancer cases to surge by almost 40 percent by 2050, warns WHO

The WHO predicts a global surge in breast cancer cases and deaths. There are several reasons for this concerning tendency. The journal Nature Medicine published the results The WHO predicts a global s

In India, 3 in 5 die following cancer diagnosis, women more affected: Study

Three in every five people in India succumb to cancer following diagnosis with women bearing a "disproportionate burden" compared to men, an analysis of global cancer data has estimated. The incidence to mortality ratio in the US was found to be about one in four, while in China it was one in two, according to the results published in 'The Lancet Regional Health Southeast Asia' journal. The Indian Council of Medical Research (ICMR) study found that India ranked third highest in cancer incidence, after China and the US, and accounted for over 10 per cent of the world's cancer-related deaths, ranking second after China. Researchers also projected that in the coming two decades, India will face a formidable challenge in managing deaths related to cancer incidence, with a yearly increase of two per cent in cases as the population ages. The team examined trends in 36 types of cancer across age groups and genders in India over the past 20 years, using the Global Cancer Observatory ...

AstraZeneca's cancer drug tops list of new brands launched in 2024

Five of top 20 drug introductions target cancer, reflecting its rising incidence in India

Fixed ceiling, retail prices to ensure affordable cancer drugs: Govt in LS

In response to a parliamentary query, the ministry said that the Department of Pharmaceuticals, through the National Pharmaceutical Pricing Authority (NPPA)

AstraZeneca reports better than expected profit on higher cancer drug sales

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts surveyed by Bloomberg

Timely cancer care improves with Ayushman Bharat in India: Lancet stud

While The Lancet study praised the health safety net created by the government, it also highlighted a critical gap in cancer care infrastructure in India

World Cancer Day 2025: Date, history, theme, significance and more

World Cancer Day is observed every year on February 4 to unite individuals and organisations in raising awareness about the challenges posed by cancer and promoting measures to combat it

Tobacco causes 40% of preventable cancer cases in India, say experts

Cancer continues to claim millions of lives in India, but tobacco consumption which is responsible for about 40 percent of cancer cases in the country is the single largest preventable cause of the disease, doctors said here on Saturday. Besides avoiding tobacco and alcohol, cancer risk can be cut down through lifestyle changes, balanced diet and regular health check-ups, experts said at a seminar organised as part of the 'Jagega Bharat Toh Bachega Bharat' campaign by the Ambagopal Foundation here. "One in five men and one in eight women in India are at risk of developing cancer, due to changing lifestyles, environmental degradation, and lack of awareness. While cancer continues to claim millions of lives, it is largely preventable if individuals adopt healthier lifestyles, avoid tobacco and alcohol consumption, maintain a balanced diet, and undergo regular health check-ups," oncologist Dr Anil D'Cruz said. Tobacco consumption remains "the single largest preventable cause of cancer"

36 life-saving medicines fully exempted from customs duty: FM Sitharaman

Budget 2025: This decision is part of a broader push to make essential healthcare more affordable, especially for cancer patients struggling with the high costs of treatment

AI-powered cancer vaccines soon? Oracle's Larry Ellison reveals big plans

At the launch of Stargate Project, Oracle's Ellison said that AI could assist in identifying the cancer fragments early through a simple blood test, followed by gene sequencing of the tumour

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget

To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties for high-tech instruments

Health cover against cancer: Check policy for exclusions, sub-limits

Cancer-specific policies, which only cover cancer, are available as indemnity-based or fixed-benefit plans

Eli Lilly to buy cancer drugmaker Scorpion Therapeutics for up to $2.5 bn

Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors

Mankind Pharma inks pact with Innovent for immunotherapy drug in India

Drug used to treat non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma will be priced competitively